Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
Key facts
- Who runs it
- Alcon Research
- Where
- Fort Worth, Jacksonville, Liverpool, Salt Lake City, Torrance, and Tulsa, United StatesSee the 6 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- People taking part
- 470 people enrolled
- Started
- 19 Sept 2023
- Ended
- 21 Aug 2026
- Type of study
- Interventional, 4 groups
- Treatments tested
- Clareon Vivity IOL - Non Toric
- Clareon Vivity IOL - Toric
- Clareon PanOptix Trifocal IOL - Non Toric
- Clareon PanOptix Trifocal IOL - Toric
- Record updated
- 2 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Subject or legally authorized representative must be able to understand and sign an approved Informed Consent Form
- Subject must have had bilateral implantation of Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOLs between 3-6 months prior to enrollment
- Subject must have a documented medical history and required pre-operative baseline information available for retrospective data collection
- Other protocol-defined inclusion criteria may apply
Who cannot take part
- Subject is currently participating in another investigational drug or device study
- Subject has had corneal refractive surgery after Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOL implantation
- Subject is pregnant at the time of enrollment
- Other protocol-defined exclusion criteria may apply
Where in United States
Also in 1 other country, 1 site
- Chu Eye InstituteFort Worth, United States
- Levenson Eye AssociatesJacksonville, United States
- Eye Surgeons of CNYLiverpool, United States
- The Eye Institute of UtahSalt Lake City, United States
- Wolstan & Goldberg Eye AssociatesTorrance, United States
- Tulsa OphthalmologyTulsa, United States
About the trial
What the trial wants to find out
The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.
The 4 groups in the trial
- Clareon Vivity IOL - Non ToricTreatment being tested
Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon Vivity IOL.
- Clareon Vivity IOL - ToricTreatment being tested
Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon Vivity IOL.
- Clareon PanOptix IOL - Non ToricTreatment being tested
Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon PanOptix IOL.
Treatment: Clareon PanOptix Trifocal IOL - Non Toric
- Clareon PanOptix IOL - ToricTreatment being tested
Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon PanOptix IOL.
Treatment: Clareon PanOptix Trifocal IOL - Toric
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Evaluation of Safety and Performance of Clareon Presbyopia-Correcting Intraocular Lenses (IOLs)
- Record updated
- 2 September 2026